ERBB2 and breast carcinoma: Here we evaluated the molecular signaling that is activated by nelfinavir treatment in two HER2 negative breast cancer cell lines (MCF-7 and MDA-MB231), based on previous works which have already demonstrated its effectiveness in these kind of cell [11, 71, 72].